Browse the corpus

©2013 UpToDate ® Print Email Benefit of clopidogrel in CURE increases over time Impact of clopidogrel compared with placebo on the incidence of cardiovascular death, MI, or stroke in the CURE trial of patients with a non-ST elevation acute coronary syndrome within first 30 days (left panel) and, among those who were event-free at that time, from 31 days to 12 months. In both time periods, clopidogrel therapy was associated with increasing benefit over time (relative risk 0.79 and 0.82, respectively). Data from Yusuf S, Mehta SR, Zhao F, et al. Circulation 2003; 107:966.